TY - JOUR T1 - Immunity after COVID-19: protection or sensitization? JF - medRxiv DO - 10.1101/2020.05.21.20108860 SP - 2020.05.21.20108860 AU - Antoine Danchin AU - Gabriel Turinici Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/10/2020.05.21.20108860.abstract N2 - Motivated by historical and present clinical observations, we discuss the possible unfavorable evolution of the immunity (similar to documented antibody-dependent enhancement scenarios) after a first infection with COVID-19. More precisely we ask the question of how the epidemic outcomes are affected if the initial infection does not provide immunity but rather sensitization to future challenges. We first provide background comparison with the 2003 SARS epidemic. Then we use a compartmental epidemic model structured by immunity level that we fit to available data; using several scenarios of the fragilization dynamics, we derive quantitative insights into the additional expected numbers of severe cases and deaths.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLogistic support from the MODCOV19 platform is acknowledged.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research only involves theoretical epidemiological data, no IRB oversight is required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data used is available from public sources that have been cited. ER -